Loading...
Evotec and Apeiron Biologics announce collaboration on cancer immunotherapy
07-Jan-2013
- Germany
Advertisement
Evotec AG announced that Evotec and Apeiron Biologics have entered into a research collaboration with the objective of developing immunomodulatory lead compounds for the treatment of cancer.
Apeiron Biologics will contribute in vitro and in vivo pharmacology expertise to this collaboration while Evotec will be responsible for medicinal chemistry as well as chemical proteomics.